Optimist Retirement Group LLC Cuts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Optimist Retirement Group LLC decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,005 shares of the medical equipment provider’s stock after selling 219 shares during the quarter. Optimist Retirement Group LLC’s holdings in Lantheus were worth $241,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Seven Eight Capital LP acquired a new stake in shares of Lantheus in the 2nd quarter valued at about $1,523,000. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Lantheus by 20.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 7,025 shares of the medical equipment provider’s stock valued at $564,000 after buying an additional 1,202 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Lantheus in the 2nd quarter valued at approximately $209,000. Peregrine Asset Advisers Inc. purchased a new position in Lantheus in the 2nd quarter valued at approximately $3,669,000. Finally, Renaissance Technologies LLC increased its stake in Lantheus by 142.8% in the 2nd quarter. Renaissance Technologies LLC now owns 215,431 shares of the medical equipment provider’s stock valued at $17,297,000 after purchasing an additional 126,700 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 2.5 %

Shares of NASDAQ:LNTH opened at $108.14 on Thursday. The stock has a market capitalization of $7.50 billion, a PE ratio of 16.51 and a beta of 0.50. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a fifty day moving average price of $106.08 and a 200 day moving average price of $83.62. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. During the same quarter in the previous year, the business posted $1.40 EPS. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. Analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the subject of several recent research reports. B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. JMP Securities reduced their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Redburn Atlantic began coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Truist Financial reduced their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Finally, Leerink Partners lifted their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Insider Transactions at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,852 shares of company stock valued at $3,922,001. Corporate insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.